What is the official website of Novartis Israel ?

The official website of Novartis Israel is https://www.novartis.com/il-he/.

What is Novartis Israel's cybersecurity risk score?

Novartis Israel has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Israel experienced?

According to Rankiteo, Novartis Israel currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Israel been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Israel has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Israel have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Israel is not certified under SOC 2 Type 1.

Does Novartis Israel have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Israel does not hold a SOC 2 Type 2 certification.

Does Novartis Israel comply with GDPR ?

According to Rankiteo, Novartis Israel is not listed as GDPR compliant.

Does Novartis Israel have PCI DSS certification ?

According to Rankiteo, Novartis Israel does not currently maintain PCI DSS compliance.

Does Novartis Israel comply with HIPAA ?

According to Rankiteo, Novartis Israel is not compliant with HIPAA regulations.

Does Novartis Israel have ISO 27001 certification ?

According to Rankiteo,Novartis Israel is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Israel operate in ?

Novartis Israel operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Israel have ?

Novartis Israel employs approximately 41 people worldwide.

Does Novartis Israel own any subsidiaries ?

Novartis Israel presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Israel have ?

Novartis Israel's official LinkedIn profile has approximately 980 followers.

What is the NAICS classification code for Novartis Israel ?

Novartis Israel is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Israel have a Crunchbase profile ?

No, Novartis Israel does not have a profile on Crunchbase.

Does Novartis Israel have a LinkedIn profile ?

Yes, Novartis Israel maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-israel.

How many cybersecurity incidents has Novartis Israel experienced ?

As of October 20, 2026, Rankiteo reports that Novartis Israel has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Israel have ?

Novartis Israel has an estimated 5,778 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Israel faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Israel

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Israel Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Around 108,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/2JnT2CP

Novartis Israel

Novartis Israel CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Israel

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident History - Novartis Israel (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Israel Subsidiaries

Novartis Israel

Pharmaceutical Manufacturing

Website: https://www.novartis.com/il-he/

Company Size: 41

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Israel Similar Companies

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Loading…

NEWS

Novartis Israel CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 03, 2025 08:00 AM

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

JPMorgan has been hiring multiple senior technologists, but they're not all coming from finance. Two new managing directors (MDs),...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

July 19, 2021 07:00 AM

Rapid7 acquires IntSights for close to $400 million

The Israeli cybersecurity company is set to become Rapid7's R&D center in Israel)

Read Article

July 15, 2021 07:00 AM

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

The Israeli cybersecurity company has raised $70 million to date and counts Forbes, Novartis and Ford among its clients)

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-77684

SUMMARY

The Bluetooth Classic Hands-Free Profile HF role in subsys/bluetooth/host/classic/hfp_hf.c does not release the AT command buffers that are still queued on hf->tx_pending when the RFCOMM DLC goes down. hfp_hf_disconnected() only cancelled the work items and cleared hf->acl, and no other code path ever dequeues those buffers, so each one is permanently lost from the fixed hf_pool (CONFIG_BT_MAX_CONN + 1 buffers, i.e. two in the default configuration). The same function also left BT_HFP_HF_FLAG_CONNECTED set, and hfp_hf_create() wiped the object with memset() as soon as hf->acl was NULL, without checking whether hf->work, hf->slc_work or hf->deferred_work was still pending or running. The remote Audio Gateway peer controls the trigger end to end and needs no application involvement: an unsolicited +BCS: 1 response makes bcs_handle() call bt_hfp_hf_select_codec() and queue an AT+BCS buffer, which cannot be transmitted while BT_HFP_HF_FLAG_RX_ONGOING is set, and an immediately following RFCOMM DISC strands that buffer. Repeating the connect / +BCS / disconnect cycle a couple of times empties hf_pool for good. With the pool exhausted, HFP command sending fails permanently, and because hfp_hf_send_cmd() allocates with K_FOREVER (bt_rfcomm_create_pdu() → bt_conn_create_pdu()) from the Bluetooth RX context — where that timeout is not downgraded to K_NO_WAIT — one further +BCS from the peer parks the Bluetooth RX thread inside net_buf_alloc() with no possible waker, halting all HCI event processing until the device is rebooted. Separately, reusing the HF slot while a work handler was still queued or running allowed memset() to wipe live k_work items out from under the system workqueue, corrupting shared kernel workqueue state. Exploitation requires an established HFP session (for SSP devices L2CAP enforces authentication before the RFCOMM channel is reachable) and a build with CONFIG_BT_HFP_HF enabled.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 5.7)

cvss3

Base Score: 5.7

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.1

REFERENCES

CVE-2026-19595

SUMMARY

The user-mode syscall verifier z_vrfy_rtio_cqe_get_mempool_buffer() in subsys/rtio/rtio_syscalls.c validated its two output parameters, buff and buff_len, with K_SYSCALL_MEMORY_READ() rather than K_SYSCALL_MEMORY_WRITE(). Both are pure out-parameters: z_impl_rtio_cqe_get_mempool_buffer() stores the mempool buffer address and its length through them. The distinction is enforced by every architecture validator — arch_buffer_validate() on RISC-V PMP explicitly accepts the global __rom_region/__rodata_region for reads only, and the ARM MPU validators accept P_RO_U_RO and P_RW_U_RO regions for reads only — so a read-validated pointer is not necessarily writable by the calling thread. An unprivileged user-mode thread that has been granted access to an RTIO context (rtio_access_grant()) can invoke the rtio_cqe_get_mempool_buffer() syscall with buff/buff_len pointing at memory it may read but not write, and with a completion-queue entry whose flags field it fully controls (only RTIO_CQE_FLAG_MEMPOOL_BUFFER in flags[7:0] is required; flags[19:8] and flags[31:20] supply the block index and count). The kernel then performs a pointer-sized and a 4-byte store through those addresses while running in supervisor mode. Reaching the store requires CONFIG_USERSPACE together with CONFIG_RTIO_SYS_MEM_BLOCKS, the configuration behind RTIO_DEFINE_WITH_MEMPOOL; without the latter the implementation returns -ENOTSUP and writes nothing. Two outcomes follow. If the target lies in a memory-domain partition declared K_MEM_PARTITION_P_RW_U_RO (privileged read-write, user read-only), the kernel-mode store succeeds and deposits partly attacker-chosen values into memory the memory domain had marked read-only for that thread, bypassing the partition's write protection. If the target lies in globally readable but unwritable memory such as .text/.rodata in flash, the store faults in kernel mode; the fault is delivered to z_fatal_error() and the default k_sys_fatal_error_handler() halts or reboots the device, giving an unprivileged thread a reliable full denial of service. The read-permission check does bound the damage: the address must still be readable by the calling thread, so kernel-private memory cannot be targeted and no confidential data is disclosed. The fix replaces both checks with K_SYSCALL_MEMORY_WRITE(), so a thread lacking write permission is terminated by K_OOPS before the implementation runs; the cqe argument correctly remains read-validated.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:H

Impact Score

4.2

Exploitability

1.8

REFERENCES

CVE-2026-19178

SUMMARY

IBM Storage TS4500 Library 1.1.1.6 through 1.12.0.3 could allow a remote authenticated attacker to gain unauthorized administrative privileges due to a race condition.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N

Impact Score

5.2

Exploitability

1.6

REFERENCES

https://www.ibm.com/support/pages/node/7292610

CVE-2026-112991

SUMMARY

The html_to_markdown expansion module in MISP Modules contains a server-side request forgery (SSRF) vulnerability in its is_safe_url() URL validation function. The BLOCKED_RANGES list used to reject unsafe destination addresses was incomplete, omitting several critical IP address ranges. Specifically, the following ranges were not blocked: 0.0.0.0/8 (unspecified, which routes to loopback on Linux), 100.64.0.0/10 (carrier-grade NAT per RFC 6598), ::/128 (IPv6 unspecified), fc00::/7 (IPv6 Unique Local Addresses), and fe80::/10 (IPv6 link-local). The existing list only covered IPv4 loopback (127.0.0.0/8), RFC 1918 private ranges, IPv4 link-local (169.254.0.0/16), and IPv6 loopback (::1/128). An authenticated user with the ability to create or modify MISP attributes that trigger the html_to_markdown expansion module could supply URLs pointing to these unblocked internal address ranges. Because the module fetches the URL server-side to convert HTML content to Markdown, the request is made from the MISP server's network context. This allows an attacker to probe and read responses from internal services, carrier-grade NAT infrastructure, or link-local endpoints that would otherwise be unreachable from external networks. IPv4-mapped IPv6 forms (e.g., [::ffff:0.0.0.0]) also bypassed the existing checks. The security impact is primarily confidentiality: an attacker can read data served by internal services reachable from the MISP server. The MISP instance itself is not compromised, but it is abused as a proxy to access otherwise restricted network resources.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: )

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/misp/misp-modules/commit/98a1c2c2f297665dd8d4609e9cd644007a57516b

CVE-2026-112372

SUMMARY

A weakness has been identified in H3C Magic NX15 V100R017. This affects the function importprofile of the file /api/upload. This manipulation of the argument fileName causes path traversal. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.6)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:L/SI:L/SA:L/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.7

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Israel Vendor Cyber Rating & Cyber Score

Novartis Israel A.I CyberSecurity Scoring

Novartis Israel CyberSecurity News & History

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Israel (X = Date, Y = Severity)

Novartis Israel Subsidiaries

Novartis Israel

Novartis Israel Similar Companies

Lupin

Novartis

Eli Lilly and Company

MSD

Parexel

Torrent Pharmaceuticals Ltd

Sandoz

Teva Pharmaceuticals

Cipla

Novartis Israel CyberSecurity News

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Rapid7 acquires IntSights for close to $400 million

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Israel CyberSecurity News & History

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Israel (X = Date, Y = Severity)

Novartis Israel Subsidiaries

Novartis Israel

Novartis Israel Similar Companies

Lupin

Novartis

Eli Lilly and Company

MSD

Parexel

Torrent Pharmaceuticals Ltd

Sandoz

Teva Pharmaceuticals

Cipla

Novartis Israel CyberSecurity News

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Rapid7 acquires IntSights for close to $400 million

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo